Real-world Use of Remdesivir for the Treatment of Patients Admitted to Italian Hospitals with COVID-19: the Nationwide Retrospective FADOI-RECOVER Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Jul 8

PMID 37422621

Authors

Filippo Pieralli

Fulvio Pomero

Francesco Dentali

Claudio Norbiato

Tiziana Attardo

Susanna Vicari

Elena Magnani

Maria Antonietta Marzilli

Paola Piccolo

Antonella Valerio

Dario Manfellotto

Affiliations

Soon will be listed here.

Abstract

Background: Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization.

Methods: This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020-September 2021), who were treated with remdesivir.

Results: One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes.

Conclusion: In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.

References

Alsayed H, Saheb Sharif-Askari F, Sharif-Askari N, Al Sayed Hussain A, Hamid Q, Halwani R . Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. PLoS One. 2021; 16(10):e0258643. PMC: 8547637. DOI: 10.1371/journal.pone.0258643. View

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

Zaccagnini G, Berni A, Pieralli F . Correlation of non-invasive oxygenation parameters with paO2/FiO2 ratio in patients with COVID-19 associated ARDS. Eur J Intern Med. 2022; 96:117-119. PMC: 8687749. DOI: 10.1016/j.ejim.2021.12.015. View

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

Beckerman R, Gori A, Jeyakumar S, Malin J, Paredes R, Povoa P . Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Sci Rep. 2022; 12(1):9622. PMC: 9186282. DOI: 10.1038/s41598-022-13680-6. View

Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D . Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021; 22(2):209-221. PMC: 8439621. DOI: 10.1016/S1473-3099(21)00485-0. View

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

10.

Montagnani A, Pieralli F, Gnerre P, Vertulli C, Manfellotto D . COVID-19 pandemic and Internal Medicine Units in Italy: a precious effort on the front line. Intern Emerg Med. 2020; 15(8):1595-1597. PMC: 7394267. DOI: 10.1007/s11739-020-02454-5. View

11.

Ohl M, Miller D, Lund B, Kobayashi T, Miell K, Beck B . Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. JAMA Netw Open. 2021; 4(7):e2114741. PMC: 8283561. DOI: 10.1001/jamanetworkopen.2021.14741. View

12.

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

13.

Siegel D, Hui H, Doerffler E, Clarke M, Chun K, Zhang L . Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017; 60(5):1648-1661. DOI: 10.1021/acs.jmedchem.6b01594. View

14.

Goguet E, Powers 3rd J, Olsen C, Tribble D, Davies J, Illinik L . Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers. Open Forum Infect Dis. 2022; 9(3):ofac030. PMC: 8860153. DOI: 10.1093/ofid/ofac030. View

15.

Mazzone A, Mumoli N . Reorganizing Italian Internal Medicine wards for COVID 19. Eur J Intern Med. 2020; 77:143. PMC: 7190484. DOI: 10.1016/j.ejim.2020.04.059. View

16.

Mehta R, Bansal S, Bysani S, Kalpakam H . A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. Int J Infect Dis. 2021; 106:71-77. PMC: 7908839. DOI: 10.1016/j.ijid.2021.02.092. View

17.

Pieralli F, Vannucchi V, Olivotto I . The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. Eur J Intern Med. 2020; 77:163-164. PMC: 7253977. DOI: 10.1016/j.ejim.2020.05.040. View

18.

Sheahan T, Sims A, Leist S, Schafer A, Won J, Brown A . Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11(1):222. PMC: 6954302. DOI: 10.1038/s41467-019-13940-6. View

19.

Elsawah H, Elsokary M, Abdallah M, Elshafie A . Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2020; 31(4):e2187. DOI: 10.1002/rmv.2187. View

20.

Kaka A, MacDonald R, Linskens E, Langsetmo L, Vela K, Duan-Porter W . Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2022; 175(5):701-709. PMC: 8924790. DOI: 10.7326/M21-4784. View